QuickView: Multiple data readouts in coming quarters
In its Q2 results on 6 August, Cerulean confirmed its clinical programme isprogressing to plan and continues to expect numerous critical data readouts
over the next 12 months. Most notably, results from its Phase II trial of
CRLX101 in renal cell cancer (RCC) will be announced in Q216 while initial
clinical data for CRLX301 are expected in Q4 of this year. We highlight that
recent announcements by two peers progressing first- and second-line
treatments for RCC could bode well for CRLX101 as a leading contender in
the third- and fourth-line RCC setting in this indication.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.